Fusion Antibodies PLC
FAB
Company Profile
Business description
Fusion Antibodies PLC is in the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It has single segment of research, development and manufacture of recombinant proteins and antibodies. It has presence in UK, Rest of Europe, and North America and Rest of World.
Contact
1 Springbank Road
Springbank Industrial Estate
Dunmurry
BelfastBT17 0QL
GBRT: +44 2890432800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
18
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,779.46 | 31.80 | -0.41% |
| DAX 40 | 25,314.40 | 57.35 | -0.23% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,693.75 | 31.28 | -0.29% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |